ReWalk Stock Triples as Robotic Suit for Stroke Victims Gets FDA Nod
This article is for subscribers only.
Shares of ReWalk Robotics Ltd. tripled after the Food and Drug Administration said the small-cap device company could start selling its ReStore soft exoskeleton-suit system.
ReStore is meant to be used at rehabilitation centers in the U.S. for people who are having trouble walking after a stroke. The company plans to sell the system for $28,900 and will also offer leasing options.